{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:42:39Z","timestamp":1793241759412,"version":"4.5.0"},"reference-count":168,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"publisher","award":["20220101281JC"],"award-info":[{"award-number":["20220101281JC"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020230","name":"Health Commission of Jilin Province","doi-asserted-by":"publisher","award":["2020Q009"],"award-info":[{"award-number":["2020Q009"]}],"id":[{"id":"10.13039\/501100020230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.intimp.2023.109990","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T11:04:40Z","timestamp":1678446280000},"page":"109990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Advances in antibody-based drugs and their delivery through the blood-brain barrier for targeted therapy and immunotherapy of gliomas"],"prefix":"10.1016","volume":"117","author":[{"given":"Xin","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyou","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongrui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiesuo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1617-9960","authenticated-orcid":false,"given":"Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.intimp.2023.109990_b0005","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/neuonc\/nou087","article-title":"The epidemiology of glioma in adults: a \u201cstate of the science\u201d review","volume":"16","author":"Ostrom","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.intimp.2023.109990_b0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.omto.2019.07.002","article-title":"B7\u2013H3 as a Novel CAR-T Therapeutic Target for Glioblastoma","volume":"14","author":"Tang","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"issue":"17","key":"10.1016\/j.intimp.2023.109990_b0015","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/jama.2013.280319","article-title":"Glioblastoma and other malignant gliomas: a clinical review","volume":"310","author":"Omuro","year":"2013","journal-title":"J. Am. Med. Assoc."},{"issue":"3","key":"10.1016\/j.intimp.2023.109990_b0020","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1158\/2159-8290.CD-20-1474","article-title":"Diffuse Glioma Heterogeneity and Its Therapeutic Implications","volume":"11","author":"Nicholson","year":"2021","journal-title":"Cancer Discov."},{"issue":"Suppl 9","key":"10.1016\/j.intimp.2023.109990_b0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12437","article-title":"Seizure characteristics and prognostic factors of gliomas","volume":"54","author":"Kerkhof","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.intimp.2023.109990_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121709","article-title":"Brain-targeting biomimetic nanoparticles for codelivery of celastrol and LY2157299 for reversing glioma immunosuppression","volume":"619","author":"Zhu","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.intimp.2023.109990_b0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fonc.2019.00041","article-title":"Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities","volume":"9","author":"Daniel","year":"2019","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2023.109990_b0040","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/ane.12966","article-title":"Improved survival of Swedish glioblastoma patients treated according to Stupp","volume":"138","author":"Bruhn","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.intimp.2023.109990_b0045","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: Treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2023.109990_b0050","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/PPO.0000000000000544","article-title":"The Challenges and Future of Immunotherapy for Gliomas","volume":"27","author":"Wu","year":"2021","journal-title":"Cancer J."},{"key":"10.1016\/j.intimp.2023.109990_b0055","article-title":"Neoantigen: A New Breakthrough in Tumor Immunotherapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2023.109990_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/biom11081131","article-title":"Transportation of Single-Domain Antibodies through the Blood-Brain Barrier","volume":"11","author":"Ruiz-Lopez","year":"2021","journal-title":"Biomolecules"},{"issue":"12","key":"10.1016\/j.intimp.2023.109990_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126442","article-title":"Brain Disposition of Antibody-Based Therapeutics: Dogma, Approaches and Perspectives","volume":"22","author":"Kouhi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0070","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.xphs.2019.05.031","article-title":"Considerations for the Design of Antibody-Based Therapeutics","volume":"109","author":"Goulet","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.intimp.2023.109990_b0075","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.neuropharm.2016.03.014","article-title":"Antibody therapies in CNS diseases","volume":"120","author":"Freskg\u00e5rd","year":"2017","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.intimp.2023.109990_b0080","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1517\/14712598.4.9.1453","article-title":"Monoclonal antibodies for brain tumour treatment","volume":"4","author":"Boskovitz","year":"2004","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0085","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"19","key":"10.1016\/j.intimp.2023.109990_b0090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910373","article-title":"Prognostic and Predictive Biomarkers in Gliomas","volume":"22","author":"\u015aledzi\u0144ska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5301\/ijbm.5000301","article-title":"EGFR as a clinical marker in glioblastomas and other gliomas","volume":"33","author":"Saadeh","year":"2018","journal-title":"Int. J. Biol. Markers"},{"issue":"29","key":"10.1016\/j.intimp.2023.109990_b0100","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.1016\/j.biomaterials.2013.06.007","article-title":"EGRF conjugated PEGylated nanographene oxide for targeted chemotherapy and photothermal therapy","volume":"34","author":"Yang","year":"2013","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.intimp.2023.109990_b0105","doi-asserted-by":"crossref","first-page":"e0162978","DOI":"10.1371\/journal.pone.0162978","article-title":"Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma","volume":"11","author":"Hicks","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.intimp.2023.109990_b0110","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.intimp.2023.109990_b0115","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1111\/j.1349-7006.2008.00945.x","article-title":"Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III","volume":"99","author":"Fukai","year":"2008","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.intimp.2023.109990_b0120","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3171\/2021.3.PEDS20738","article-title":"Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial","volume":"28","author":"McCrea","year":"2021","journal-title":"J. Neurosurg. Pediatr."},{"issue":"3","key":"10.1016\/j.intimp.2023.109990_b0125","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2174\/1568026618666180112162412","article-title":"Cetuximab and the Head and Neck Squamous Cell Cancer","volume":"18","author":"Concu","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"issue":"8","key":"10.1016\/j.intimp.2023.109990_b0130","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/neuonc\/noz073","article-title":"Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma","volume":"21","author":"Greenall","year":"2019","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2023.109990_b0135","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/1541-7786.MCR-11-0531","article-title":"In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy","volume":"10","author":"Gajadhar","year":"2012","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0140","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11060-019-03140-z","article-title":"Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study","volume":"143","author":"Fleischhack","year":"2019","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.intimp.2023.109990_b0145","doi-asserted-by":"crossref","DOI":"10.1177\/10732748211053927","article-title":"Nimotuzumab as Additional Therapy for GLIOMA in Pediatric and Adolescent: A Systematic Review","volume":"29","author":"Parenrengi","year":"2022","journal-title":"Cancer Control."},{"issue":"12","key":"10.1016\/j.intimp.2023.109990_b0150","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1517\/14712598.2012.733367","article-title":"Nimotuzumab treatment of malignant gliomas","volume":"12","author":"Bode","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2023.109990_b0155","first-page":"819","article-title":"Profile of nimotuzumab in the treatment of high-grade glioma","volume":"8","author":"Yang","year":"2015","journal-title":"Onco Targets Ther."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0160","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4161\/mabs.1.1.7509","article-title":"Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin","volume":"1","author":"Ramakrishnan","year":"2009","journal-title":"MAbs"},{"issue":"7903","key":"10.1016\/j.intimp.2023.109990_b0165","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2023.109990_b0170","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","article-title":"Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy","volume":"10","author":"Nazha","year":"2020","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2023.109990_b0175","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s11060-020-03470-3","article-title":"GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma","volume":"147","author":"Marx","year":"2020","journal-title":"J Neuro-Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2023.109990_b0180","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ijc.32533","article-title":"Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside","volume":"146","author":"Fleurence","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2023.109990_b0185","doi-asserted-by":"crossref","first-page":"e0198508","DOI":"10.1371\/journal.pone.0198508","article-title":"Robo1 and vimentin regulate radiation-induced motility of human glioblastoma cells","volume":"13","author":"Nguemgo Kouam","year":"2018","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.intimp.2023.109990_b0190","first-page":"337","article-title":"High Expression of Vimentin is Associated With Progression and a Poor Outcome in Glioblastoma","volume":"26","author":"Zhao","year":"2018","journal-title":"Appl Immunohisto M M."},{"issue":"2","key":"10.1016\/j.intimp.2023.109990_b0195","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3233\/HAB-170326","article-title":"Pritumumab, the first therapeutic antibody for glioma patients","volume":"26","author":"Babic","year":"2018","journal-title":"Hum. Antibodies"},{"issue":"4","key":"10.1016\/j.intimp.2023.109990_b0200","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3233\/HAB-2009-0209","article-title":"Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab","volume":"18","author":"Glassy","year":"2009","journal-title":"Hum. Antibodies"},{"issue":"7","key":"10.1016\/j.intimp.2023.109990_b0205","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ymthe.2022.05.011","article-title":"Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors","volume":"30","author":"Yin","year":"2022","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.intimp.2023.109990_b0210","first-page":"4702","article-title":"IL13RA2 is overexpressed in malignant gliomas and related to clinical outcome of patients","volume":"12","author":"Zeng","year":"2020","journal-title":"Am. J. Transl. Res."},{"issue":"21","key":"10.1016\/j.intimp.2023.109990_b0215","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1158\/1078-0432.CCR-12-0319","article-title":"Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells","volume":"18","author":"Kong","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0220","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s13046-019-1319-4","article-title":"Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12\/CXCR4","volume":"38","author":"Yi","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.intimp.2023.109990_b0225","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1007\/s12031-021-01817-7","article-title":"Integrated Gene Expression and Methylation Analyses Identify DLL3 as a Biomarker for Prognosis of Malignant Glioma","volume":"71","author":"Maimaiti","year":"2021","journal-title":"J. Mol. Neurosci."},{"issue":"4","key":"10.1016\/j.intimp.2023.109990_b0230","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/1078-0432.CCR-18-2312","article-title":"Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma","volume":"25","author":"Spino","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0235","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41698-021-00214-y","article-title":"A phase I\/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors","volume":"5","author":"Mansfield","year":"2021","journal-title":"npj Precis. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0240","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11060-019-03200-4","article-title":"CD146 is highly expressed in glioma stem cells and acts as a cell cycle regulator","volume":"144","author":"Yawata","year":"2019","journal-title":"J. Neurooncol"},{"issue":"47","key":"10.1016\/j.intimp.2023.109990_b0245","doi-asserted-by":"crossref","first-page":"E6525","DOI":"10.1073\/pnas.1502648112","article-title":"Targeting CD146 with a 64Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas","volume":"112","author":"Yang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.intimp.2023.109990_b0250","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00018-022-04420-0","article-title":"CD146 increases stemness and aggressiveness in glioblastoma and activates YAP signaling","volume":"79","author":"Liang","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.intimp.2023.109990_b0255","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-3-030-48457-6_9","article-title":"Tenascin-C Function in Glioma: Immunomodulation and Beyond","volume":"1272","author":"Yalcin","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"issue":"6","key":"10.1016\/j.intimp.2023.109990_b0260","first-page":"1042","article-title":"Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study","volume":"46","author":"Akabani","year":"2005","journal-title":"J. Nucl. Med."},{"issue":"7","key":"10.1016\/j.intimp.2023.109990_b0265","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/sj.bjc.6600818","article-title":"Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT)","volume":"88","author":"De Santis","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0270","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.2005.03.4082","article-title":"Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results","volume":"24","author":"Reardon","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2023.109990_b0275","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1586\/14737140.7.5.675","article-title":"Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients","volume":"7","author":"Reardon","year":"2007","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.intimp.2023.109990_b0280","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.609657","article-title":"Meta-Analyses of Splicing and Expression Quantitative Trait Loci Identified Susceptibility Genes of Glioma","volume":"12","author":"Patro","year":"2021","journal-title":"Front. Genet."},{"issue":"4","key":"10.1016\/j.intimp.2023.109990_b0285","doi-asserted-by":"crossref","first-page":"574","DOI":"10.4149\/neo_2015_069","article-title":"Effect of TNFRSF6B neutralization antibody on cell growth suppression and apoptosis induction in glioma cells","volume":"62","author":"Ruan","year":"2015","journal-title":"Neoplasma"},{"issue":"12","key":"10.1016\/j.intimp.2023.109990_b0290","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/jgm.1110","article-title":"Targeting malignant gliomas with a glial fibrillary acidic protein (GFAP)-selective oncolytic adenovirus","volume":"9","author":"Horst","year":"2007","journal-title":"J. Gene Med."},{"issue":"15","key":"10.1016\/j.intimp.2023.109990_b0295","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.7314\/APJCP.2014.15.15.6315","article-title":"Expression of neuronal markers, NFP and GFAP, in malignant astrocytoma","volume":"15","author":"Hashemi","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0300","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11481-008-9123-5","article-title":"Targeted transport of 125I-labeled antibody to GFAP and AMVB1 in an experimental rat model of C6 glioma","volume":"4","author":"Chekhonin","year":"2009","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.intimp.2023.109990_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103283","article-title":"Cytoskeletal proteins as glioblastoma biomarkers and targets for therapy: A systematic review","volume":"160","author":"Zottel","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"6","key":"10.1016\/j.intimp.2023.109990_b0310","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1111\/jcmm.13547","article-title":"Humanization of fibroblast growth factor 1 single-chain antibody and validation for its antitumorigenic efficacy in breast cancer and glioma cells","volume":"22","author":"He","year":"2018","journal-title":"J. Cell Mol. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0315","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1096\/fj.11-191064","article-title":"Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation","volume":"26","author":"Wang","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2023.109990_b0320","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/OTT.S38628","article-title":"Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges","volume":"6","author":"Rahmathulla","year":"2013","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.intimp.2023.109990_b0325","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1186\/s12885-015-1538-9","article-title":"A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model","volume":"15","author":"Towner","year":"2015","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2023.109990_b0330","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1515\/revneuro-2020-0062","article-title":"VEGF levels in patients with glioma: a systematic review and meta-analysis","volume":"32","author":"Seyedmirzaei","year":"2021","journal-title":"Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0335","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/srao.2003.50005","article-title":"Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy","volume":"13","author":"Siemann","year":"2003","journal-title":"Semin. Radiat. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2023.109990_b0340","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/archneurol.2010.11","article-title":"Bevacizumab for malignant gliomas","volume":"67","author":"Iwamoto","year":"2010","journal-title":"Arch. Neurol."},{"issue":"8","key":"10.1016\/j.intimp.2023.109990_b0345","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11864-016-0418-0","article-title":"Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future","volume":"17","author":"Chen","year":"2016","journal-title":"Curr. Treat. Options Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0350","first-page":"vdab132","article-title":"ELTD1 as a multi-focal target for malignant gliomas: preclinical studies","volume":"3","author":"Zalles","year":"2021","journal-title":"Neurooncol Adv."},{"issue":"28","key":"10.1016\/j.intimp.2023.109990_b0355","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2023.109990_b0360","doi-asserted-by":"crossref","first-page":"972","DOI":"10.2174\/092986712799320646","article-title":"Efficacy and safety of bevacizumab in glioblastomas","volume":"19","author":"De Fazio","year":"2012","journal-title":"Curr. Med. Chem."},{"issue":"6","key":"10.1016\/j.intimp.2023.109990_b0365","first-page":"2083","article-title":"Vascular endothelial growth factor receptor 1 in glioblastoma-associated microglia\/macrophages","volume":"43","author":"Lisi","year":"2020","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0370","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13046-017-0577-2","article-title":"The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells","volume":"36","author":"Atzori","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0375","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1038\/s41598-021-85385-1","article-title":"The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab","volume":"11","author":"Carvalho","year":"2021","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.intimp.2023.109990_b0380","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.intimp.2023.109990_b0385","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bbrc.2022.03.045","article-title":"Anti-VEGFR2 monoclonal antibody(MSB0254) inhibits angiogenesis and tumor growth by blocking the signaling pathway mediated by VEGFR2 in glioblastoma","volume":"604","author":"Chen","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.intimp.2023.109990_b0390","doi-asserted-by":"crossref","first-page":"e0260103","DOI":"10.1371\/journal.pone.0260103","article-title":"H19- and hsa-miR-338-3p-mediated NRP1 expression is an independent predictor of poor prognosis in glioblastoma","volume":"16","author":"Liu","year":"2021","journal-title":"PLoS One"},{"issue":"86","key":"10.1016\/j.intimp.2023.109990_b0395","doi-asserted-by":"crossref","first-page":"35655","DOI":"10.18632\/oncotarget.26273","article-title":"Expression of neuropilin-1 is linked to glioma associated microglia and macrophages and correlates with unfavorable prognosis in high grade gliomas","volume":"9","author":"Caponegro","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.intimp.2023.109990_b0400","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1166\/jbn.2013.1623","article-title":"Inhibitory effect of neuropilin-1 monoclonal antibody (NRP-1 MAb) on glioma tumor in mice","volume":"9","author":"Chen","year":"2013","journal-title":"J. Biomed. Nanotechnol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0405","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1227\/NEU.0b013e318276b29d","article-title":"ELTD1, a potential new biomarker for gliomas","volume":"72","author":"Towner","year":"2013","journal-title":"Neurosurgery."},{"issue":"2","key":"10.1016\/j.intimp.2023.109990_b0410","first-page":"175","article-title":"ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models","volume":"19","author":"Ziegler","year":"2017","journal-title":"Neuro Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2023.109990_b0415","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1111\/jcmm.14867","article-title":"Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model","volume":"24","author":"Zalles","year":"2020","journal-title":"J. Cell Mol. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0420","first-page":"93","article-title":"Targeting ELTD1, an angiogenesis marker for glioblastoma (GBM), also affects VEGFR2: molecular-targeted MRI assessment","volume":"9","author":"Ziegler","year":"2019","journal-title":"Am J Nucl Med Molec."},{"issue":"3","key":"10.1016\/j.intimp.2023.109990_b0425","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","article-title":"The Microenvironmental Landscape of Brain Tumors","volume":"31","author":"Quail","year":"2017","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.intimp.2023.109990_b0430","doi-asserted-by":"crossref","DOI":"10.3390\/cells10092257","article-title":"The Interplay between Glioblastoma and Its Microenvironment","volume":"10","author":"Dapash","year":"2021","journal-title":"Cells."},{"issue":"21","key":"10.1016\/j.intimp.2023.109990_b0435","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215347","article-title":"PD-L1\/PD-1 Axis in Glioblastoma Multiforme","volume":"20","author":"Litak","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0440","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13046-019-1085-3","article-title":"Challenges and potential of PD-1\/PD-L1 checkpoint blockade immunotherapy for glioblastoma","volume":"38","author":"Wang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2023.109990_b0445","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","article-title":"Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma","volume":"25","author":"Zhao","year":"2019","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.intimp.2023.109990_b0450","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/neuonc\/noaa260","article-title":"Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study","volume":"23","author":"Sahebjam","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.intimp.2023.109990_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.101977","article-title":"Biomarkers for immunotherapy response in head and neck cancer","volume":"84","author":"Gavrielatou","year":"2020","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2023.109990_b0460","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0465","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11060-017-2643-1","article-title":"Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma","volume":"136","author":"Fried","year":"2018","journal-title":"J. Neurooncol"},{"issue":"17","key":"10.1016\/j.intimp.2023.109990_b0470","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","article-title":"Immune Checkpoint Inhibitors: Basics and Challenges","volume":"26","author":"Li","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0475","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1038\/s41467-021-22885-8","article-title":"Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas","volume":"12","author":"Amoozgar","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2023.109990_b0480","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/963037","article-title":"A Combination of Systemic and Intracranial Anti-CD25 Immunotherapy Elicits a Long-Time Survival in Murine Model of Glioma","volume":"2009","author":"Poirier","year":"2009","journal-title":"J. Oncol."},{"key":"10.1016\/j.intimp.2023.109990_b0485","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40425-016-0132-2","article-title":"Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma","volume":"4","author":"Patel","year":"2016","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0490","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ijc.22607","article-title":"CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo","volume":"121","author":"Grauer","year":"2007","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.intimp.2023.109990_b0495","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/13543784.2020.1826436","article-title":"Ipilimumab: an investigational immunotherapy for glioblastoma","volume":"29","author":"Youssef","year":"2020","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0500","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12885-020-6624-y","article-title":"A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol","volume":"20","author":"Brown","year":"2020","journal-title":"BMC Cancer"},{"issue":"17","key":"10.1016\/j.intimp.2023.109990_b0505","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.7150\/thno.43991","article-title":"Tandem CAR-T cells targeting CD70 and B7\u2013H3 exhibit potent preclinical activity against multiple solid tumors","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0510","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40478-021-01167-w","article-title":"The expression of B7\u2013H3 isoforms in newly diagnosed glioblastoma and recurrence and their functional role","volume":"9","author":"Digregorio","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"issue":"9","key":"10.1016\/j.intimp.2023.109990_b0515","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1158\/0008-5472.CAN-16-2310","article-title":"Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma","volume":"77","author":"Chen","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2023.109990_b0520","doi-asserted-by":"crossref","first-page":"15080","DOI":"10.1038\/ncomms15080","article-title":"Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth","volume":"8","author":"Shi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2023.109990_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103571","article-title":"Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma","volume":"71","author":"Foster","year":"2021","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.intimp.2023.109990_b0530","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/cns.13714","article-title":"Prospects of antibodies targeting CD47 or CD24 in the treatment of glioblastoma","volume":"27","author":"Wu","year":"2021","journal-title":"CNS Neurosci. Ther."},{"issue":"381","key":"10.1016\/j.intimp.2023.109990_b0535","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2968","article-title":"Disrupting the CD47-SIRP\u03b1 anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors","volume":"9","author":"Gholamin","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2023.109990_b0540","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jconrel.2021.01.023","article-title":"ImmunoPET-informed sequence for focused ultrasound-targeted mCD47 blockade controls glioma","volume":"331","author":"Sheybani","year":"2021","journal-title":"J. Control. Release"},{"issue":"16","key":"10.1016\/j.intimp.2023.109990_b0545","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1073\/pnas.1525360113","article-title":"Ang-2\/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival","volume":"113","author":"Kloepper","year":"2016","journal-title":"PNAS"},{"issue":"6","key":"10.1016\/j.intimp.2023.109990_b0550","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9060640","article-title":"A Rational Designed Novel Bispecific Antibody for the Treatment of GBM","volume":"9","author":"Sun","year":"2021","journal-title":"Biomedicines."},{"issue":"9","key":"10.1016\/j.intimp.2023.109990_b0555","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2015800118","article-title":"Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity","volume":"118","author":"Pituch","year":"2021","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2023.109990_b0560","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-015-0227-0","article-title":"Bispecific antibodies and their applications","volume":"8","author":"Fan","year":"2015","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2023.109990_b0565","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1158\/1535-7163.MCT-14-1078","article-title":"AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma","volume":"14","author":"Hamblett","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pep.2012.02.011","article-title":"Synthesis and purification of a toxin-linked conjugate targeting epidermal growth factor receptor in Escherichia coli","volume":"83","author":"Ma","year":"2012","journal-title":"Protein Expr. Purif."},{"issue":"7","key":"10.1016\/j.intimp.2023.109990_b0575","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/neuonc\/nop069","article-title":"Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo","volume":"12","author":"Nagane","year":"2010","journal-title":"Neuro Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2023.109990_b0580","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/PAI.0000000000000702","article-title":"Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction","volume":"27","author":"Gondim","year":"2019","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0585","first-page":"51","article-title":"Tumor localization of an anti-TGF-beta antibody and its effects on gliomas","volume":"38","author":"Hulper","year":"2011","journal-title":"Int. J. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2023.109990_b0590","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/mab.2017.0031","article-title":"Establishment of CMab-43, a Sensitive and Specific Anti-CD133 Monoclonal Antibody, for Immunohistochemistry","volume":"36","author":"Itai","year":"2017","journal-title":"Monoclon Antib Immunodiagn Immunother."},{"issue":"22","key":"10.1016\/j.intimp.2023.109990_b0595","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1158\/1078-0432.CCR-09-1499","article-title":"Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma","volume":"15","author":"He","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.intimp.2023.109990_b0600","article-title":"Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer Immunotherapies","volume":"11","author":"Mk","year":"2021","journal-title":"J Pers Med."},{"issue":"2","key":"10.1016\/j.intimp.2023.109990_b0605","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1124\/jpet.117.246249","article-title":"Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models","volume":"365","author":"Szab\u00f3","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2023.109990_b0610","doi-asserted-by":"crossref","first-page":"e0153550","DOI":"10.1371\/journal.pone.0153550","article-title":"Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2023.109990_b0615","doi-asserted-by":"crossref","first-page":"120758","DOI":"10.1016\/j.ijpharm.2021.120758","article-title":"Highlights in targeted nanoparticles as a delivery strategy for glioma treatment","volume":"604","author":"Luiz","year":"2021","journal-title":"Int J Pharm."},{"issue":"9","key":"10.1016\/j.intimp.2023.109990_b0620","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/j.xphs.2017.04.080","article-title":"Routes for Drug Translocation Across the Blood-Brain Barrier: Exploiting Peptides as Delivery Vectors","volume":"106","author":"Kristensen","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0625","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"50","key":"10.1016\/j.intimp.2023.109990_b0630","doi-asserted-by":"crossref","first-page":"27885","DOI":"10.1021\/acsami.5b09934","article-title":"Multi-targeting Peptide-Functionalized Nanoparticles Recognized Vasculogenic Mimicry, Tumor Neovasculature, and Glioma Cells for Enhanced Anti-glioma Therapy","volume":"7","author":"Feng","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0635","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12951-022-01610-7","article-title":"Overcoming the blood-brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches","volume":"20","author":"Mitusova","year":"2022","journal-title":"J Nanobiotechnology."},{"key":"10.1016\/j.intimp.2023.109990_b0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121395","article-title":"Comparison of three synthetic transferrin mimetic small peptides to promote the blood-brain barrier penetration of vincristine liposomes for improved glioma targeted therapy","volume":"613","author":"Mojarad-Jabali","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"22","key":"10.1016\/j.intimp.2023.109990_b0645","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1016\/j.biomaterials.2014.03.068","article-title":"Nanoparticles functionalized with Pep-1 as potential glioma targeting delivery system via interleukin 13 receptor \u03b12-mediated endocytosis","volume":"35","author":"Wang","year":"2014","journal-title":"Biomaterials"},{"issue":"16","key":"10.1016\/j.intimp.2023.109990_b0650","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1016\/j.bmc.2018.08.006","article-title":"Dual-targeting for brain-specific liposomes drug delivery system: Synthesis and preliminary evaluation","volume":"26","author":"Peng","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.intimp.2023.109990_b0655","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot5407","article-title":"Preparation of Trojan horse liposomes (THLs) for gene transfer across the blood-brain barrier","volume":"2010","author":"Pardridge","year":"2010","journal-title":"Cold Spring Harb Protoc"},{"key":"10.1016\/j.intimp.2023.109990_b0660","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.bbrc.2020.10.076","article-title":"Angiopep-2 modified lipid-coated mesoporous silica nanoparticles for glioma targeting therapy overcoming BBB","volume":"534","author":"Zhu","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.intimp.2023.109990_b0665","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1039\/D1BM01506K","article-title":"Blood-brain barrier penetrating liposomes with synergistic chemotherapy for glioblastoma treatment","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomater. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2023.109990_b0670","doi-asserted-by":"crossref","first-page":"e1800219","DOI":"10.1002\/ardp.201800219","article-title":"Liposomes actively recognizing the glucose transporter GLUT(1) and integrin \u03b1(v) \u03b2(3) for dual-targeting of glioma","volume":"352","author":"Fu","year":"2019","journal-title":"Arch Pharm (Weinheim)."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0675","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/1061186X.2016.1184272","article-title":"Nano carriers for drug transport across the blood-brain barrier","volume":"25","author":"Li","year":"2017","journal-title":"J. Drug Target."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0680","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1038\/s41467-019-11719-3","article-title":"Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy","volume":"10","author":"Galstyan","year":"2019","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.intimp.2023.109990_b0685","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1021\/acs.biomac.1c01103","article-title":"Small, Smart, and LDLR-Specific Micelles Augment Sorafenib Therapy of Glioblastoma","volume":"22","author":"Wei","year":"2021","journal-title":"Biomacromolecules"},{"issue":"2","key":"10.1016\/j.intimp.2023.109990_b0690","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.apsb.2018.01.004","article-title":"Liposomes and lipid disks traverse the BBB and BBTB as intact forms as revealed by two-step F\u00f6rster resonance energy transfer imaging","volume":"8","author":"Dai","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0695","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1021\/mp700086j","article-title":"Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability","volume":"5","author":"Dhanikula","year":"2008","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.intimp.2023.109990_b0700","doi-asserted-by":"crossref","DOI":"10.3390\/ph14080711","article-title":"In Vitro Studies on Nasal Formulations of Nanostructured Lipid Carriers (NLC) and Solid Lipid Nanoparticles (SLN)","volume":"14","author":"Costa","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.intimp.2023.109990_b0705","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.2147\/IJN.S348559","article-title":"Supramolecular Hydrogel Based Post-Surgical Implant System for Hydrophobic Drug Delivery Against Glioma Recurrence","volume":"17","author":"Wanjale","year":"2022","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0710","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12943-020-01189-3","article-title":"Exosomal noncoding RNAs in Glioma: biological functions and potential clinical applications","volume":"19","author":"Cheng","year":"2020","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0715","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.nano.2016.08.029","article-title":"Efficacy of NGR peptide-modified PEGylated quantum dots for crossing the blood-brain barrier and targeted fluorescence imaging of glioma and tumor vasculature","volume":"13","author":"Huang","year":"2017","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0720","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12951-019-0462-6","article-title":"Chlorotoxin peptide-functionalized polyethylenimine-entrapped gold nanoparticles for glioma SPECT\/CT imaging and radionuclide therapy","volume":"17","author":"Zhao","year":"2019","journal-title":"J Nanobiotechnology."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0725","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/1566523217666170605115829","article-title":"Glioblastoma Targeted Gene Therapy Based on pEGFP\/p53-Loaded Superparamagnetic Iron Oxide Nanoparticles","volume":"17","author":"Eslaminejad","year":"2017","journal-title":"Curr. Gene Ther."},{"issue":"11","key":"10.1016\/j.intimp.2023.109990_b0730","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.1021\/acsami.5b11730","article-title":"Tailoring Particle Size of Mesoporous Silica Nanosystem To Antagonize Glioblastoma and Overcome Blood-Brain Barrier","volume":"8","author":"Mo","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.intimp.2023.109990_b0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120645","article-title":"An update on actively targeted liposomes in advanced drug delivery to glioma","volume":"602","author":"Mojarad-Jabali","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100365","article-title":"Targeting immunoliposomes to EGFR-positive glioblastoma","volume":"7","author":"Kasenda","year":"2022","journal-title":"ESMO Open."},{"key":"10.1016\/j.intimp.2023.109990_b0745","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.2147\/IJN.S157935","article-title":"Fe(3)O(4)@Au composite magnetic nanoparticles modified with cetuximab for targeted magneto-photothermal therapy of glioma cells","volume":"13","author":"Lu","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.intimp.2023.109990_b0750","doi-asserted-by":"crossref","first-page":"8875","DOI":"10.2147\/IJN.S270208","article-title":"A Dual Receptor Targeting- and BBB Penetrating- Peptide Functionalized Polyethyleneimine Nanocomplex for Secretory Endostatin Gene Delivery to Malignant Glioma","volume":"15","author":"Lu","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.intimp.2023.109990_b0755","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.2147\/IJN.S318266","article-title":"Efficient Anti-Glioma Therapy Through the Brain-Targeted RVG15-Modified Liposomes Loading Paclitaxel-Cholesterol Complex","volume":"16","author":"Xin","year":"2021","journal-title":"Int. J. Nanomed."},{"issue":"9","key":"10.1016\/j.intimp.2023.109990_b0760","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1039\/C9NA00056A","article-title":"Dual targeting of folate receptor-expressing glioma tumor-associated macrophages and epithelial cells in the brain using a carbon nanosphere-cationic folate nanoconjugate","volume":"1","author":"Elechalawar","year":"2019","journal-title":"Nanoscale Adv."},{"issue":"36","key":"10.1016\/j.intimp.2023.109990_b0765","doi-asserted-by":"crossref","first-page":"9171","DOI":"10.1016\/j.biomaterials.2013.08.039","article-title":"LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"},{"issue":"15","key":"10.1016\/j.intimp.2023.109990_b0770","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1158\/1078-0432.CCR-20-3760","article-title":"Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models","volume":"27","author":"Sabbagh","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0775","doi-asserted-by":"crossref","first-page":"e0166061","DOI":"10.1371\/journal.pone.0166061","article-title":"Effects on P-Glycoprotein Expression after Blood-Brain Barrier Disruption Using Focused Ultrasound and Microbubbles","volume":"12","author":"Aryal","year":"2017","journal-title":"PLoS One"},{"issue":"Suppl 6","key":"10.1016\/j.intimp.2023.109990_b0780","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1093\/neuonc\/noac208","article-title":"Laser hyperthermia: Past, present, and future","volume":"24","author":"Schupper","year":"2022","journal-title":"Neuro Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2023.109990_b0785","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci12121627","article-title":"Magnetic Resonance-Guided Laser Interstitial Thermal Therapy for Management of Low-Grade Gliomas and Radiation Necrosis: A Single-Institution Case Series","volume":"12","author":"Scherschinski","year":"2022","journal-title":"Brain Sci."},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0790","first-page":"vdac040","article-title":"Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma","volume":"4","author":"de Groot","year":"2022","journal-title":"Neurooncol Adv."},{"issue":"5","key":"10.1016\/j.intimp.2023.109990_b0795","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3109\/09687688.2014.937468","article-title":"The blood-brain barrier: structure, function and therapeutic approaches to cross it","volume":"31","author":"Tajes","year":"2014","journal-title":"Mol. Membr. Biol."},{"issue":"Suppl 2","key":"10.1016\/j.intimp.2023.109990_b0800","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/nou354","article-title":"Convection-enhanced delivery for the treatment of glioblastoma","volume":"17 Suppl 2","author":"Vogelbaum","year":"2015","journal-title":"Neuro Oncol."},{"issue":"23","key":"10.1016\/j.intimp.2023.109990_b0805","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24234312","article-title":"Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials","volume":"24","author":"Bruinsmann","year":"2019","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.intimp.2023.109990_b0810","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ijpharm.2011.09.008","article-title":"Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals","volume":"420","author":"Qin","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"12","key":"10.1016\/j.intimp.2023.109990_b0815","first-page":"4402","article-title":"Carrier-free highly drug-loaded biomimetic nanosuspensions encapsulated by cancer cell membrane based on homology and active targeting for the treatment of glioma","volume":"6","author":"Fan","year":"2021","journal-title":"Bioact. Mater."},{"issue":"40","key":"10.1016\/j.intimp.2023.109990_b0820","doi-asserted-by":"crossref","first-page":"34603","DOI":"10.1021\/acsami.7b05997","article-title":"Substance P Mediated DGLs Complexing with DACHPt for Targeting Therapy of Glioma","volume":"9","author":"Sun","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.intimp.2023.109990_b0825","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1186\/s12951-021-01180-0","article-title":"Combined integrin alphavbeta3 and lactoferrin receptor targeted docetaxel liposomes enhance the brain targeting effect and anti-glioma effect","volume":"19","author":"Qi","year":"2021","journal-title":"J Nanobiotechnology."},{"issue":"10","key":"10.1016\/j.intimp.2023.109990_b0830","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1021\/acs.jmedchem.7b00527","article-title":"Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the Blood-Brain Barrier","volume":"60","author":"Monaco","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2023.109990_b0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2021.112033","article-title":"Docetaxel-loaded folate-modified TPGS-transfersomes for glioblastoma multiforme treatment","volume":"124","author":"Luiz","year":"2021","journal-title":"Mater Sci Eng C Mater Biol Appl."},{"issue":"2","key":"10.1016\/j.intimp.2023.109990_b0840","doi-asserted-by":"crossref","first-page":"e1800219","DOI":"10.1002\/ardp.201800219","article-title":"Liposomes actively recognizing the glucose transporter GLUT(1) and integrin alpha(v) beta(3) for dual-targeting of glioma","volume":"352","author":"Fu","year":"2019","journal-title":"Arch Pharm (Weinheim)."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923003119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923003119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:57:54Z","timestamp":1761587874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923003119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":168,"alternative-id":["S1567576923003119"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109990","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in antibody-based drugs and their delivery through the blood-brain barrier for targeted therapy and immunotherapy of gliomas","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.109990","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109990"}}